Cutaneous melanoma is related to immune suppression in kidney transplant recipients

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 8, 2009, Pages 2297-2303

  Vajdic, Claire M ^a,g   Van Leeuwen, Marina T ^a,b   Webster, Angela C ^d,e   McCredie, Margaret R E ^f   Stewart, John H ^f   Chapman, Jeremy R ^c   Amin, Janaki ^b   McDonald, Stephen P ^d   Grulich, Andrew E ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF OTAGO   (New Zealand)

^g PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOCYTE ANTIBODY;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROTEIN DEPLETION; RECIPIENT; RENAL REPLACEMENT THERAPY;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFANT; KIDNEY TRANSPLANTATION; MALE; MELANOMA; MIDDLE AGED; RISK FACTORS; SKIN NEOPLASMS; SOLAR SYSTEM; YOUNG ADULT;

EID: 68949101710     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0278     Document Type: Article

References (50)

1. Kripke ML. Antigenicity of murine skin tumors induced by ultraviolet light. J Natl Cancer Inst 1974;53:1333-6.
2. Fisher MS, Kripke ML. Systemic alteration induced in mice by ultraviolet light irradiation and its relationship to ultraviolet carcinogenesis. Proc Natl Acad Sci U S A 1977;74:1688-92.
3. Dean JH, Greene MH, Reimer RR, et al. Immunologic abnormalities in melanoma-prone families. J Natl Cancer Inst 1979;63:1139-45.
4. Greene MH, Young TI, Clark WH, Jr. Malignant melanoma in renal-transplant recipients. Lancet 1981;1:1196-9.
5. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007;370:59-67.
6. McGregor JM, Barker JN, MacDonald DM. The development of excess numbers of melanocytic naevi in an immunosuppressed identical twin. Clin Exp Dermatol 1991;16:131-2.
7. Smith CH, McGregor JM, Barker JN, Morris RW, Rigden SP, MacDonald DM. Excess melanocytic nevi in children with renal allografts. J Am Acad Dermatol 1993;28:51-5.
8. Grob JJ, Bastuji-Garin S, Vaillant L, et al. Excess of nevi related to immunodeficiency: a study in HIV-infected patients and renal transplant recipients. J Invest Dermatol 1996;107:694-7.
9. Hughes BR, Cunliffe WJ, Bailey CC. Excess benign melanocytic naevi after chemotherapy for malignancy in childhood. BMJ 1989;299:88-91.
10. Belloni-Fortina A, Piaserico S, Tonin E, Alaibac M. Melanoma and immunosuppression. Dermatology 2009;218:88.
11. Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA 2006;296:2823-31.
12. van Leeuwen MT, Grulich AE, McDonald SP, et al. Immunosuppression and other risk factors for lip cancer after kidney transplantation. Cancer Epidemiol Biomarkers Prev 2009;18:561-9.
13. Australia and New Zealand Liver Transplant Registry (ANZLTR). ANZLTR 19th Report. Brisbane: Australia and New Zealand Liver Transplant Registry; 2008.
14. Australian Institute of Health and Welfare (AIHW) and Australasian Association of Cancer Registries (AACR). Cancer in Australia: an overview 2006. AIHW Cat. No. CAN 32. Cancer Series No. 37. Canberra: Australian Institute of Health and Welfare; 2007.
15. Marcen R, Teruel JL. Patient outcomes after kidney allograft loss. Transplant Rev (Orlando) 2008;22:62-72.
16. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999;40:177-86.
17. Birkeland SA, Lokkegaard H, Storm HH. Cancer risk in patients on dialysis and after renal transplantation. Lancet 2000;355:1886-7.
18. Lindelof B, Sigurgeirsson B, Gabel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 2000;143:513-9.
19. Adami J, Gabel H, Lindelof B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003;89: 1221-7.
20. Moloney FJ, Comber H, O'Lorcain P, O'Kelly P, Conlon PJ, Murphy GM. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006;154:498-504.
21. Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant 2007;7:941-8.
22. Bastiaannet E, Homan-van der Heide JJ, Ploeg RJ, Hoekstra HJ. No increase of melanoma after kidney transplantation in the northern part of The Netherlands. Melanoma Res 2007;17:349-53.
23. Piaserico S, Alaibac M, Fortina AB, Peserico A. Clinical and dermatoscopic fading of post-transplant eruptive melanocytic nevi after suspension of immunosuppressive therapy. J Am Acad Dermatol 2006; 54:338-40.
24. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996;61:274-8.
25. Hollenbeak CS, Todd MM, Billingsley EM, Harper G, Dyer AM, Lengerich EJ. Increased incidence of melanoma in renal transplantation recipients. Cancer 2005;104:1962-7.
26. Muller TF, Grebe SO, Neumann MC, et al. Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. Transplantation 1997;64:1432-7.
27. Thibaudin D, Alamartine E, Mariat C, Absi L, Berthoux F. Long-term kinetic of T-lymphocyte subsets in kidney-transplant recipients: influence of anti-T-cell antibodies and association with posttransplant malignancies. Transplantation 2005;80:1514-7.
28. O'Donovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005;309:1871-4.
29. Perrett CM, Walker SL, O'Donovan P, et al. Azathioprine treatment photosensitizes human skin to ultraviolet A radiation. Br J Dermatol 2008;159:198-204.
30. Yarosh DB, Pena AV, Nay SL, Canning MT, Brown DA. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 2005;125:1020-5.
31. Canning MT, Nay SL, Pena AV, Yarosh DB. Calcineurin inhibitors reduce nuclear localization of transcription factor NFAT in UV-irradiated keratinocytes and reduce DNA repair. J Mol Histol 2006;37:285-91.
32. Rivera A, Maxwell SA. The p53-induced gene-6 (proline oxidase) mediates apoptosis through a calcineurin-dependent pathway. J Biol Chem 2005;280:29346-54.
33. Hartmann A, Blaszyk H, Cunningham JS, et al. Overexpression and mutations of p53 in metastatic malignant melanomas. Int J Cancer 1996;67:313-7.
34. Leveque L, Dalac S, Dompmartin A, et al. Melanoma in organ transplant patients. Ann Dermatol Venereol 2000;127:160-5.
35. Le Mire L, Hollowood K, Gray D, Bordea C, Wojnarowska F. Melanomas in renal transplant recipients. Br J Dermatol 2006;154:472-7.
36. Barker JN, MacDonald DM. Eruptive dysplastic naevi following renal transplantation. Clin Exp Dermatol 1988;13:123-5.
37. Alaibac M, Piaserico S, Rossi CR, et al. Eruptive melanocytic nevi in patients with renal allografts: report of 10 cases with dermoscopic findings. J Am Acad Dermatol 2003;49:1020-2.
38. Duvic M, Lowe L, Rapini RP, Rodriguez S, Levy ML. Eruptive dysplastic nevi associated with human immunodeficiency virus infection. Arch Dermatol 1989;125:397-401.
39. Richert S, Bloom EJ, Flynn K, Seraly MP. Widespread eruptive dermal and atypical melanocytic nevi in association with chronic myelocytic leukemia: case report and review of the literature. J Am Acad Dermatol 1996;35:326-9.
40. Lanoy E, Dores GM, Madeleine MM, Toro JR, Fraumeni JF, Jr., Engels EA. Epidemiology of nonkeratinocytic skin cancers among persons with AIDS in the United States. AIDS 2009;23:385-93.
41. Guerrini JS, Pretet JL, Mougin C, Aubin F. Human papillomavirus in melanoma. Br J Dermatol 2006;154:572.
42. Ambretti S, Venturoli S, Mirasoli M, et al. Assessment of the presence of mucosal human papillomaviruses in malignant melanomas using combined fluorescent in situ hybridization and chemiluminescent immunohistochemistry. Br J Dermatol 2007;156:38-44.
43. Bouwes Bavinck JN, Feltkamp M, Struijk L, ter Schegget J. Human papillomavirus infection and skin cancer risk in organ transplant recipients. J Investig Dermatol Symp Proc 2001;6:207-11.
44. Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). ANZDATA Registry Report 2004. Adelaide: Australia and New Zealand Dialysis and Transplant Registry; 2004.
45. In: Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, editors. Cancer incidence in five continents, volume VIII. IARC scientific publication No. 155. Lyon: IARC Press; 2002.
46. Grulich AE, Wan X, Coates M, Day P, Kaldor JM. Validation of a non-identifying method of linking cancer and AIDS register data. J Epidemiol Biostat 1996;1:207-212.
47. Setoguchi S, Solomon DH, Weinblatt ME, et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:2757-64.
48. Buchbinder R, Barber M, Heuzenroeder L, et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 2008;59:794-9.
49. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11.
50. Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497-502.